Compare Stocks → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ENTXNASDAQ:ERYPNASDAQ:PSTIOTCMKTS:QNNTFNASDAQ:TARA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTXEntera Bio$1.99-11.2%$1.58$0.52▼$3.35$57.31M1.7212,725 shs300,731 shsERYPERYTECH Pharma$3.10$4.66$0.30▼$1.47$105.77M2.6993,510 shsN/APSTIPluristem Therapeutics$1.24$0.95▼$3.45$32.35M1.91715,259 shs2,128 shsQNNTFQuantum Genomics Société Anonyme$0.10$0.10$0.10▼$0.10N/A0.22N/AN/ATARAProtara Therapeutics$2.64-4.0%$3.76$1.04▼$5.24$30.18M1.71206,084 shs207,887 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTXEntera Bio+0.90%-15.79%+58.84%+129.72%+157.47%ERYPERYTECH Pharma0.00%0.00%0.00%-34.04%+236.96%PSTIPluristem Therapeutics0.00%0.00%0.00%0.00%0.00%QNNTFQuantum Genomics Société Anonyme0.00%0.00%0.00%0.00%-97.03%TARAProtara Therapeutics+0.73%-11.00%-31.25%+43.98%-10.13%SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENTXEntera Bio1.7538 of 5 stars3.53.00.00.03.90.00.0ERYPERYTECH PharmaN/AN/AN/AN/AN/AN/AN/AN/APSTIPluristem TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AQNNTFQuantum Genomics Société AnonymeN/AN/AN/AN/AN/AN/AN/AN/ATARAProtara Therapeutics1.9667 of 5 stars3.53.00.00.02.40.80.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENTXEntera Bio3.00Buy$10.00402.51% UpsideERYPERYTECH PharmaN/AN/AN/AN/APSTIPluristem TherapeuticsN/AN/AN/AN/AQNNTFQuantum Genomics Société AnonymeN/AN/AN/AN/ATARAProtara Therapeutics3.00Buy$23.00771.21% UpsideCurrent Analyst RatingsLatest ENTX, TARA, PSTI, QNNTF, and ERYP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/8/2024TARAProtara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.004/2/2024ENTXEntera BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.003/14/2024TARAProtara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENTXEntera Bio$130K440.86N/AN/A$0.36 per share5.53ERYPERYTECH Pharma$32.66M3.24N/AN/A$0.80 per share3.88PSTIPluristem Therapeutics$20K0.00N/AN/A$1.80 per share0.00QNNTFQuantum Genomics Société AnonymeN/AN/AN/AN/AN/AN/ATARAProtara TherapeuticsN/AN/AN/AN/A$6.01 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENTXEntera Bio-$8.89M-$0.31N/AN/AN/AN/A-101.78%-83.90%5/3/2024 (Estimated)ERYPERYTECH Pharma-$240KN/A0.00∞N/AN/AN/AN/AN/APSTIPluristem Therapeutics-$49.87M-$1.47N/AN/AN/AN/A-100.63%-55.46%N/AQNNTFQuantum Genomics Société AnonymeN/AN/A0.00∞N/AN/AN/AN/AN/ATARAProtara Therapeutics-$40.42M-$3.57N/AN/AN/AN/A-49.71%-43.82%5/2/2024 (Estimated)Latest ENTX, TARA, PSTI, QNNTF, and ERYP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/13/2024Q4 2023TARAProtara Therapeutics-$1.03-$0.90+$0.13-$0.90N/AN/A3/8/2024Q4 2023ENTXEntera Bio-$0.08-$0.07+$0.01-$0.07N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENTXEntera BioN/AN/AN/AN/AN/AERYPERYTECH PharmaN/AN/AN/AN/AN/APSTIPluristem TherapeuticsN/AN/AN/AN/AN/AQNNTFQuantum Genomics Société AnonymeN/AN/AN/AN/AN/ATARAProtara TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENTXEntera BioN/A10.3210.32ERYPERYTECH Pharma0.323.653.65PSTIPluristem Therapeutics0.578.228.22QNNTFQuantum Genomics Société AnonymeN/AN/AN/ATARAProtara TherapeuticsN/A11.1711.17OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENTXEntera Bio14.11%ERYPERYTECH Pharma1.09%PSTIPluristem Therapeutics16.94%QNNTFQuantum Genomics Société AnonymeN/ATARAProtara Therapeutics38.13%Insider OwnershipCompanyInsider OwnershipENTXEntera Bio8.90%ERYPERYTECH Pharma1.94%PSTIPluristem Therapeutics5.40%QNNTFQuantum Genomics Société AnonymeN/ATARAProtara Therapeutics18.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableENTXEntera Bio1728.80 million26.24 millionOptionableERYPERYTECH Pharma4934.12 million33.46 millionNot OptionablePSTIPluristem Therapeutics15332.35 million30.60 millionOptionableQNNTFQuantum Genomics Société Anonyme3N/AN/ANot OptionableTARAProtara Therapeutics2611.43 million9.33 millionOptionableENTX, TARA, PSTI, QNNTF, and ERYP HeadlinesSourceHeadlineProtara Therapeutics (TARA) Price Target Decreased by 11.76% to 27.54msn.com - April 17 at 12:11 PMProtara Therapeutics, Inc. (TARA)finance.yahoo.com - April 15 at 6:45 PMHere's Why Protara Therapeutics (TARA) Is a Great 'Buy the Bottom' Stock Nowzacks.com - April 12 at 10:56 AMProtara Therapeutics (NASDAQ:TARA) Stock Rating Reaffirmed by HC Wainwrightamericanbankingnews.com - April 9 at 3:46 AMBuy Rating for Protara Therapeutics’ TARA-002 Based on Promising Clinical Data and Market Potential in NMIBC Treatmentmarkets.businessinsider.com - April 9 at 2:25 AMProtara Therapeutics Shares Interim Data From Bladder Cancer Study, Raises $45M Via Equitymsn.com - April 5 at 3:10 PMProtara Reaches Alignment With FDA On A Registrational Path Forward For IV Choline Chloridemarkets.businessinsider.com - April 5 at 10:10 AMProtara Announces Positive Data From TARA-002 Trial In Bladder Cancer; Stock Upmarkets.businessinsider.com - April 5 at 10:10 AMProtara Therapeutics Announces Oversubscribed $45 Million Private Placement Financingglobenewswire.com - April 5 at 8:04 AMProtara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutritionglobenewswire.com - April 5 at 8:02 AMProtara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBCglobenewswire.com - April 5 at 8:00 AM3 Stocks That Could Help You Retire on a Private Islandinvestorplace.com - March 23 at 6:00 AMBuy Rating on Protara Therapeutics Backed by Promising TARA-002 Clinical Trials and Significant Market Opportunitymarkets.businessinsider.com - March 13 at 6:27 PMProtara Therapeutics: Q4 Earnings Snapshotchron.com - March 13 at 1:26 PMProtara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updateglobenewswire.com - March 13 at 8:00 AMTARA Aug 2024 7.500 callfinance.yahoo.com - March 3 at 11:42 PMTARA May 2024 2.500 putfinance.yahoo.com - March 3 at 11:42 PMNon Muscle Invasive Bladder Cancer Pipeline Outlook Report 2024theglobeandmail.com - February 28 at 7:58 PMProtara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conferenceglobenewswire.com - February 28 at 8:00 AMNorthSea Therapeutics commences Phase IIa trial for IFALD therapymsn.com - February 22 at 7:53 PMWe're Keeping An Eye On Protara Therapeutics' (NASDAQ:TARA) Cash Burn Ratefinance.yahoo.com - February 17 at 8:43 AMCG Oncology's Lead Bladder Cancer Drug Offers A Strong Potential Revenue Stream With Buyout Optionalityseekingalpha.com - January 25 at 3:04 PMOppenheimer Reaffirms Their Buy Rating on Protara Therapeutics (TARA)markets.businessinsider.com - December 2 at 7:37 PMProtara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncologyfinance.yahoo.com - November 30 at 12:38 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsEntera BioNASDAQ:ENTXEntera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and hGh for the GH deficiency. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.ERYTECH PharmaNASDAQ:ERYPERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.Pluristem TherapeuticsNASDAQ:PSTIPluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.Quantum Genomics Société AnonymeOTCMKTS:QNNTFQuantum Genomics Société Anonyme, a biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases. The company develops its drugs based on brain inhibition mechanism of Aminopeptidase A: BAPAI, a triple-action therapeutic platform primarily to treat high blood pressure and heart failure. It is developing firibastat, a treatment for high blood pressure, and in combination with others anti-hypertensive drugs. The company also is involved in the development of drugs for the treatment of high blood pressure as monotherapy and the prevention, as well as treatment of heart failure. Quantum Genomics Société Anonyme was incorporated in 2005 and is based in Paris, France.Protara TherapeuticsNASDAQ:TARAProtara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. The company is headquartered in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.